PURE BIOSCIENCE Narrows Losses Amidst Shifting Revenue Mix
Ticker: PURE · Form: 10-Q · Filed: Jun 16, 2025 · CIK: 1006028
| Field | Detail |
|---|---|
| Company | Pure Bioscience, Inc. (PURE) |
| Form Type | 10-Q |
| Filed Date | Jun 16, 2025 |
| Risk Level | high |
| Sentiment | mixed |
Sentiment: mixed
Topics: Bioscience, Quarterly Earnings, Net Loss, Revenue Decline, Royalty Income, SEC Filing, Chemical Products
Related Tickers: PURE
TL;DR
**PURE is still losing money, but the royalty revenue jump is a glimmer of hope; watch for sustained profitability, not just reduced losses.**
AI Summary
PURE BIOSCIENCE, INC. reported a net loss of $1,000 for the three months ended April 30, 2025, a significant improvement from the $10,000 net loss in the prior-year period. For the nine months ended April 30, 2025, the company posted a net loss of $1,000, compared to a $10,000 net loss for the same period in 2024. Total revenue for the three months ended April 30, 2025, was $1,000, consistent with the prior-year period. Product revenue for the nine months ended April 30, 2025, was $1,000, down from $10,000 in the prior-year period, representing a 90% decrease. Royalty revenue, however, increased to $1,000 for the nine months ended April 30, 2025, from $100 in the prior-year period, a substantial 900% increase. The company's strategic outlook focuses on leveraging its PURE Hard Surface and SilvErion technologies, despite the overall decline in product sales. The persistent net losses highlight ongoing operational challenges and the need for increased revenue generation.
Why It Matters
For investors, PURE's ability to significantly reduce its net loss, despite a sharp decline in product revenue, signals a potential shift in operational efficiency or cost management. The dramatic increase in royalty revenue, from $100 to $1,000, suggests that licensing or intellectual property monetization could become a more critical component of its business model, potentially impacting its competitive standing against larger chemical product manufacturers. Employees might face continued pressure to innovate and drive new revenue streams, while customers could see a greater emphasis on the company's PURE Hard Surface and SilvErion technologies. The broader market will watch if this shift towards royalty-based income can sustain the company in a competitive bioscience landscape.
Risk Assessment
Risk Level: high — The company reported a net loss of $1,000 for the three months ended April 30, 2025, and a net loss of $1,000 for the nine months ended April 30, 2025, indicating continued unprofitability. Product revenue for the nine months decreased by 90% from $10,000 to $1,000, highlighting a significant decline in core sales, which poses a substantial risk to long-term viability.
Analyst Insight
Investors should exercise extreme caution and conduct thorough due diligence. While the reduced net loss is positive, the 90% drop in product revenue is a major red flag. Monitor future filings for sustained profitability and a clear strategy to reverse the product sales decline, or for further growth in royalty income.
Financial Highlights
- debt To Equity
- N/A
- revenue
- $1,000
- operating Margin
- N/A
- total Assets
- N/A
- total Debt
- N/A
- net Income
- -$1,000
- eps
- N/A
- gross Margin
- N/A
- cash Position
- N/A
- revenue Growth
- 0%
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Product Revenue | $1,000 | -90% |
| Royalty Revenue | $1,000 | +900% |
Key Numbers
- $1,000 — Net Loss (Q3 2025) (Significant improvement from $10,000 loss in Q3 2024)
- $1,000 — Net Loss (9 months 2025) (Reduced from $10,000 loss in 9 months 2024)
- $1,000 — Total Revenue (Q3 2025) (Consistent with prior-year period)
- $1,000 — Product Revenue (9 months 2025) (90% decrease from $10,000 in prior-year period)
- $1,000 — Royalty Revenue (9 months 2025) (900% increase from $100 in prior-year period)
Key Players & Entities
- PURE BIOSCIENCE, INC. (company) — filer of the 10-Q
- $1,000 (dollar_amount) — net loss for three months ended April 30, 2025
- $10,000 (dollar_amount) — net loss for three months ended April 30, 2024
- $1,000 (dollar_amount) — total revenue for three months ended April 30, 2025
- $10,000 (dollar_amount) — product revenue for nine months ended April 30, 2024
- $1,000 (dollar_amount) — product revenue for nine months ended April 30, 2025
- $100 (dollar_amount) — royalty revenue for nine months ended April 30, 2024
- $1,000 (dollar_amount) — royalty revenue for nine months ended April 30, 2025
- PURE Hard Surface (company) — company technology
- SilvErion (company) — company technology
FAQ
What were PURE BIOSCIENCE's net losses for the recent quarter and nine-month period?
PURE BIOSCIENCE, INC. reported a net loss of $1,000 for the three months ended April 30, 2025, and a net loss of $1,000 for the nine months ended April 30, 2025.
How did PURE BIOSCIENCE's product revenue change in the nine months ended April 30, 2025?
Product revenue for PURE BIOSCIENCE, INC. decreased by 90% to $1,000 for the nine months ended April 30, 2025, down from $10,000 in the prior-year period.
What was the trend in PURE BIOSCIENCE's royalty revenue?
Royalty revenue for PURE BIOSCIENCE, INC. increased significantly by 900% to $1,000 for the nine months ended April 30, 2025, up from $100 in the prior-year period.
What are PURE BIOSCIENCE's key technologies mentioned in the filing?
PURE BIOSCIENCE, INC. focuses on leveraging its PURE Hard Surface and SilvErion technologies, which are central to its product offerings.
Is PURE BIOSCIENCE currently profitable?
No, PURE BIOSCIENCE, INC. is not currently profitable, reporting net losses of $1,000 for both the recent quarter and the nine-month period.
What is the primary risk highlighted by PURE BIOSCIENCE's 10-Q filing?
The primary risk is the significant 90% decline in product revenue for the nine months ended April 30, 2025, indicating challenges in core sales despite reduced net losses.
How does the current net loss compare to the previous year for PURE BIOSCIENCE?
The net loss for PURE BIOSCIENCE, INC. for the three months ended April 30, 2025, was $1,000, a substantial improvement from the $10,000 net loss in the prior-year period.
What does the increase in royalty revenue suggest for PURE BIOSCIENCE's business model?
The 900% increase in royalty revenue suggests that PURE BIOSCIENCE, INC. may be shifting towards a business model that emphasizes licensing or intellectual property monetization more heavily.
What should investors consider regarding PURE BIOSCIENCE's financial performance?
Investors should consider the mixed signals: while net losses have decreased, the sharp decline in product revenue indicates underlying sales challenges that need to be addressed for sustainable growth.
What is the overall revenue trend for PURE BIOSCIENCE for the three months ended April 30, 2025?
PURE BIOSCIENCE, INC.'s total revenue for the three months ended April 30, 2025, was $1,000, which remained consistent with the prior-year period.
Industry Context
PURE BIOSCIENCE, INC. operates in the miscellaneous chemical products sector, focusing on antimicrobial technologies. The industry is characterized by innovation in hygiene and sanitation solutions, driven by increasing global health awareness and regulatory standards. Companies in this space often face challenges related to product development cycles, market adoption, and competition from established players and new entrants.
Regulatory Implications
As a company dealing with chemical products, PURE BIOSCIENCE, INC. is subject to various regulatory bodies and standards related to product safety, efficacy, and environmental impact. Compliance with these regulations is crucial for market access and maintaining consumer trust. Any changes in regulatory requirements or failure to meet them could significantly impact the company's operations and product sales.
What Investors Should Do
- Monitor the sustainability of royalty revenue growth as a potential offset to declining product sales.
- Analyze the company's strategy for revitalizing product revenue, particularly concerning its PURE Hard Surface and SilvErion technologies.
- Evaluate the company's cash burn rate and its ability to fund operations given the persistent net losses.
Glossary
- 10-Q
- A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document is the 10-Q filing for PURE BIOSCIENCE, INC., detailing its financial status for the period ending April 30, 2025.)
- us-gaap:ProductMember
- Refers to revenue generated from the sale of the company's products. (Product revenue is a key component of PURE BIOSCIENCE, INC.'s total revenue, and its significant decline is a critical factor in the company's financial performance.)
- us-gaap:RoyaltyMember
- Income received by a company for the use of its intellectual property, patents, or trademarks by another party. (Royalty revenue has shown substantial growth for PURE BIOSCIENCE, INC., indicating a potential shift in revenue streams or successful licensing agreements.)
Year-Over-Year Comparison
For the three months ended April 30, 2025, PURE BIOSCIENCE, INC. reported a net loss of $1,000, a significant improvement from the $10,000 net loss in the prior-year period, with total revenue remaining consistent at $1,000. However, for the nine-month period, product revenue saw a substantial 90% decrease to $1,000, while royalty revenue surged by 900% to $1,000, indicating a significant shift in revenue composition. The company continues to face operational challenges, as evidenced by persistent net losses.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on June 16, 2025 regarding PURE BIOSCIENCE, INC. (PURE).